DKK 446.1
(-1.26%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 3.19 Billion DKK | 107.75% |
2022 | 1.53 Billion DKK | -25.53% |
2021 | 2.06 Billion DKK | 7.43% |
2020 | 1.92 Billion DKK | 20.32% |
2019 | 1.59 Billion DKK | 30.06% |
2018 | 1.22 Billion DKK | 66.81% |
2017 | 737.23 Million DKK | 6.13% |
2016 | 694.62 Million DKK | 9.44% |
2015 | 634.68 Million DKK | 6.36% |
2014 | 596.75 Million DKK | 72.02% |
2013 | 346.91 Million DKK | -33.41% |
2012 | 520.98 Million DKK | 10.97% |
2011 | 469.48 Million DKK | 4.2% |
2010 | 450.55 Million DKK | 183.94% |
2009 | 158.67 Million DKK | -29.55% |
2008 | 225.24 Million DKK | -14.48% |
2007 | 263.36 Million DKK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 10.15 Billion DKK | 183.14% |
2024 Q1 | 3.58 Billion DKK | 12.13% |
2023 FY | 3.19 Billion DKK | 107.75% |
2023 Q2 | 2.04 Billion DKK | 52.9% |
2023 Q3 | 2.17 Billion DKK | 6.14% |
2023 Q4 | 3.19 Billion DKK | 47.04% |
2023 Q1 | 1.34 Billion DKK | -12.94% |
2022 Q1 | 1.83 Billion DKK | -11.14% |
2022 Q4 | 1.53 Billion DKK | 41.06% |
2022 Q2 | 1.25 Billion DKK | -31.61% |
2022 Q3 | 1.09 Billion DKK | -13.13% |
2022 FY | 1.53 Billion DKK | -25.53% |
2021 Q2 | 1.92 Billion DKK | -11.32% |
2021 Q3 | 1.66 Billion DKK | -13.69% |
2021 Q1 | 2.16 Billion DKK | 12.74% |
2021 Q4 | 2.06 Billion DKK | 24.5% |
2021 FY | 2.06 Billion DKK | 7.43% |
2020 Q3 | 2.05 Billion DKK | -9.36% |
2020 Q1 | 1.56 Billion DKK | -2.37% |
2020 Q2 | 2.27 Billion DKK | 45.48% |
2020 FY | 1.92 Billion DKK | 20.32% |
2020 Q4 | 1.92 Billion DKK | -6.53% |
2019 Q2 | 1.22 Billion DKK | -8.97% |
2019 FY | 1.59 Billion DKK | 30.06% |
2019 Q1 | 1.35 Billion DKK | 9.82% |
2019 Q3 | 1.71 Billion DKK | 39.38% |
2019 Q4 | 1.59 Billion DKK | -6.66% |
2018 Q4 | 1.22 Billion DKK | -19.26% |
2018 Q3 | 1.52 Billion DKK | 191.7% |
2018 Q2 | 522.13 Million DKK | -15.85% |
2018 Q1 | 620.49 Million DKK | -15.83% |
2018 FY | 1.22 Billion DKK | 66.81% |
2017 FY | 737.23 Million DKK | 6.13% |
2017 Q1 | 474.2 Million DKK | -31.73% |
2017 Q3 | 828.62 Million DKK | 117.45% |
2017 Q4 | 737.23 Million DKK | -11.03% |
2017 Q2 | 381.06 Million DKK | -19.64% |
2016 Q2 | 477.45 Million DKK | -10.75% |
2016 FY | 694.62 Million DKK | 9.44% |
2016 Q1 | 534.94 Million DKK | -15.71% |
2016 Q4 | 694.62 Million DKK | 21.93% |
2016 Q3 | 569.7 Million DKK | 19.32% |
2015 Q3 | 535.74 Million DKK | 3.66% |
2015 Q4 | 634.68 Million DKK | 18.47% |
2015 FY | 634.68 Million DKK | 6.36% |
2015 Q1 | 569.23 Million DKK | -4.61% |
2015 Q2 | 516.82 Million DKK | -9.21% |
2014 Q2 | 333.09 Million DKK | -12.72% |
2014 Q4 | 596.75 Million DKK | 66.8% |
2014 Q3 | 357.77 Million DKK | 7.41% |
2014 FY | 596.75 Million DKK | 72.02% |
2014 Q1 | 381.66 Million DKK | 10.02% |
2013 FY | 346.91 Million DKK | -33.41% |
2013 Q2 | 432.71 Million DKK | -8.12% |
2013 Q4 | 346.91 Million DKK | -10.09% |
2013 Q1 | 470.96 Million DKK | -9.6% |
2013 Q3 | 385.83 Million DKK | -10.83% |
2012 FY | 520.98 Million DKK | 10.97% |
2012 Q3 | 564.08 Million DKK | 0.96% |
2012 Q4 | 520.98 Million DKK | -7.64% |
2012 Q2 | 558.71 Million DKK | 0.97% |
2012 Q1 | 553.36 Million DKK | 17.87% |
2011 FY | 469.48 Million DKK | 4.2% |
2011 Q3 | 485.13 Million DKK | -5.51% |
2011 Q4 | 469.48 Million DKK | -3.23% |
2011 Q1 | 408.81 Million DKK | -9.26% |
2011 Q2 | 513.41 Million DKK | 25.59% |
2010 Q4 | 450.55 Million DKK | 0.0% |
2010 FY | 450.55 Million DKK | 183.94% |
2009 FY | 158.67 Million DKK | -29.55% |
2008 FY | 225.24 Million DKK | -14.48% |
2007 FY | 263.36 Million DKK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ALK-Abelló A/S | 6.72 Billion DKK | 52.44% |
Bavarian Nordic A/S | 14.35 Billion DKK | 77.713% |
Genmab A/S | 35.28 Billion DKK | 90.935% |
Gubra A/S | 625.28 Million DKK | -411.59% |
Novo Nordisk A/S | 314.48 Billion DKK | 98.983% |
Orphazyme A/S | 19.31 Million DKK | -16464.173% |
Pharma Equity Group A/S | 81.33 Million DKK | -3832.96% |